Visual Abstract

Visual Abstract
Visual Abstract.
View largeDownload slide
Keywords:
Chronic kidney disease, Albuminuria testing, Hypertension , Diabetes, Racial disparities, Chronic kidney disease disparities, Safety-net clinic, Vulnerable populations

Background: Detection of chronic kidney disease (CKD) with urine albumin-to-creatinine ratio (UACR) among patients with hypertension (HTN) provides an opportunity for early treatment, potentially mitigating risk of CKD progression and cardiovascular complications. Differences in UACR testing patterns among racial/ethnic populations at risk for CKD could contribute to known disparities in CKD complications. Methods: We examined the prevalence of UACR testing among low-income adult primary care patients with HTN, defined by a new administrative code for HTN or 2 clinic blood pressures >140/90 mm Hg between January 1, 2014, and January 1, 2017, in one public health-care delivery system with a high prevalence of end-stage kidney disease among race/ethnic minorities. Logistic regression was used to identify odds of UACR testing within 1 year of a HTN diagnosis, overall, and by racial/ethnic subgroup, adjusted for demographic factors, estimated glomerular filtration rate, and HTN severity. Models were also stratified by diabetes status. Results: The cohort (n = 16,414) was racially/ethnically diverse (16% White, 21% Black, 34% Asian, 19% Hispanic, and 10% other) and 51% female. Only 35% of patients had UACR testing within 1 year of a HTN diagnosis. Among individuals without diabetes, odds of UACR testing were higher among Asians, Blacks, and Other subgroups compared to Whites (adjusted OR [aOR] 1.19; 95% CI 1.00–1.42 for Blacks; aOR 1.33; 1.13–1.56 for Asians; aOR 1.30; 1.04–1.60 for Other) but were not significantly different between Hispanics and Whites (aOR 1.17; 0.97–1.39). Among individuals with diabetes, only Asians had higher odds of UACR testing compared to Whites (aOR 1.35; 1.12–1.63). Conclusions: Prevalence of UACR testing among low-income patients with HTN is low in one public health-care delivery system, with higher odds of UACR testing among racial/ethnic minority subgroups compared to Whites without diabetes and similar odds among those with diabetes. If generalizable, less albuminuria testing may not explain higher prevalence of kidney failure in racial/ethnic minorities.

Keywords:
Chronic kidney disease, Albuminuria testing, Hypertension , Diabetes, Racial disparities, Chronic kidney disease disparities, Safety-net clinic, Vulnerable populations
1.
United States Renal Data System.
2018 USRDS annual data report: Epidemiology of kidney disease in the United States
. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2018.
2.
Nissenson AR, Collins AJ, Hurley J, Petersen H, Pereira BJ, Steinberg EP. Opportunities for improving the care of patients with chronic renal insufficiency: current practice patterns.
J Am Soc Nephrol
. 2001 Aug;12(8):1713–20.
3.
Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.
Kidney Int
. 2015 May;87(5):1055–60.
4.
Barrett BJ. Applying multiple interventions in chronic kidney disease.
Semin Dial
. 2003 Mar–Apr;16(2):157–64.
5.
Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD.
Am J Kidney Dis
. 2014 May;63(5):713–35.
6.
Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin:creatinine ratio for chronic kidney disease screening: A population-based study.
PLoS One
. 2017 Feb;12(2):e0171106.
7.
Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, et al.; Alberta Kidney Disease Network. Relation between kidney function, proteinuria, and adverse outcomes.
JAMA
. 2010 Feb;303(5):423–9.
8.
Boulware LE, Jaar BG, Tarver-Carr ME, Brancati FL, Powe NR. Screening for proteinuria in US adults: a cost-effectiveness analysis.
JAMA
. 2003 Dec;290(23):3101–14.
9.
Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD: a systematic review.
Am J Kidney Dis
. 2014 May;63(5):789–97.
10.
https://www.ncqa.org/hedis/measures/ (Accessed: October 1, 2018).
11.
National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/cg182. Accessed December 15 2018.
12.
Norris KC, Agodoa LY. Unraveling the racial disparities associated with kidney disease.
Kidney Int
. 2005 Sep;68(3):914–24.
13.
Albertus P, Morgenstern H, Robinson B, Saran R. Risk of ESRD in the United States.
Am J Kidney Dis
. 2016 Dec;68(6):862–72.
14.
Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease.
Adv Chronic Kidney Dis
. 2015 Jan;22(1):6–15.
15.
Volkova N, McClellan W, Klein M, Flanders D, Kleinbaum D, Soucie JM, et al. Neighborhood poverty and racial differences in ESRD incidence.
J Am Soc Nephrol
. 2008 Feb;19(2):356–64.
16.
Tuot DS, Grubbs V. Chronic kidney disease care in the US safety net.
Adv Chronic Kidney Dis
. 2015 Jan;22(1):66–73.
17.
Hall YN, Choi AI, Chertow GM, Bindman AB. Chronic kidney disease in the urban poor.
Clin J Am Soc Nephrol
. 2010 May;5(5):828–35.
18.
San Francisco General Hospital and Trauma Center Annual Report, Fiscal Year 2013–2014 [Accessed on March 15, 2019]. Available from: https://www.sfdph.org/dph/files/SFGHdocs/2013-2014-AnnualReport-141105.pdf.
19.
Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al.; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and -cystatin C.
N Engl J Med
. 2012 Jul;367(1):20–9.
20.
Adepoju OE, Preston MA, Gonzales G. Health Care Disparities in the Post-Affordable Care Act Era.
Am J Public Health
. 2015 Nov;105(Suppl 5):S665–7.
21.
Simonetti JA, Fine MJ, Chen YF, Simak D, Hess R. Racial comparisons of diabetes care and intermediate outcomes in a patient-centered medical home.
Diabetes Care
. 2014 Apr;37(4):993–1001.
22.
Eddy DM, Pawlson LG, Schaaf D, Peskin B, Shcheprov A, Dziuba J, et al. The potential effects of HEDIS performance measures on the quality of care.
Health Aff (Millwood)
. 2008 Sep-Oct;27(5):1429–41.
23.
Fiscella K, Sanders MR. Racial and Ethnic Disparities in the Quality of Health Care. 
Annu Rev Public Health
. 2016;37(1):375–94.
24.
Lee HM, Ahn J, Kim WR, et al. A Comparison Between Community and Academic Practices in the USA in the Management of Chronic Hepatitis B Patients Receiving Entecavir: results of the ENUMERATE Study.
Dig Dis Sci
. 2019 Feb;64(2):358–66.
25.
Lacy NL, Paulman A, Reuter MD, Lovejoy B. Why we don’t come: patient perceptions on no-shows.
Ann Fam Med
. 2004 Nov-Dec;2(6):541–5.
26.
Armstrong K, Ravenell KL, McMurphy S, Putt M. Racial/ethnic differences in physician distrust in the United States.
Am J Public Health
. 2007 Jul;97(7):1283–9.
27.
Ngo-Metzger Q, Legedza AT, Phillips RS. Asian Americans’ reports of their health care experiences. Results of a national survey.
J Gen Intern Med
. 2004 Feb;19(2):111–9.
28.
Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey: Analytic Guidelines, 2011–2014 and 2015–016.
29.
National Research Council.
Hispanics and the Future of America
. Washingon (DC): The National Academies Press; 2006.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.